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Excessive Daytime Sleepiness is Associated With Poor Medication
Adherence in Adults With Heart Failure
Abstract
Background
A relationship between excessive daytime sleepiness (EDS) and poor treatment adherence has been suspected
but not confirmed. We hypothesized that medication adherence would be poorer in adults with heart failure
(HF) and EDS and that cognitive status would be the mechanism of effect.
Methods and Results
A sample of 280 adults with chronic HF were enrolled into a prospective cohort comparison study. We
identified a cohort with EDS and a control group without EDS and further divided both groups into those
with and without mild cognitive decline. Data on medication adherence were obtained at baseline and 3 and 6
months by using the Basel Assessment of Adherence Scale. Regression analysis was used to clarify the
contribution of EDS and cognition to medication adherence and to assess relationships over 6 months after
adjusting for age, enrollment site, gender, race, functional class, depression, and premorbid intellect. At
baseline, 62% of subjects were nonadherent to their medication regime. Nonadherence was significantly more
common in those with EDS, regardless of cognitive status (P = .035). The odds of nonadherence increased by
11% for each unit increase in EDS (adjusted odds ratio 1.11; 95% confidence interval 1.05–1.19; P = .001). In
longitudinal models, there was a 10% increase in the odds of nonadherence for each unit increase in EDS (P =
.008). The only cognition measure significantly associated with medication adherence was attention (P =
.047).
Conclusions
Adults with HF and EDS are more likely to have problems adhering to their medication regimen than those
without EDS, regardless of their cognitive status. Identifying and correcting factors that interfere with sleep
may improve medication adherence.
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Abstract
Background—A relationship between excessive daytime sleepiness (EDS) and poor treatment
adherence has been suspected but not confirmed. We hypothesized that medication adherence
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would be poorer in adults with heart failure (HF) and EDS and that cognitive status would be the
mechanism of effect.
Methods—A sample of 280 adults with chronic HF was enrolled into a prospective cohort
comparison study. We identified a cohort with EDS and a control group without EDS and further
divided both groups into those with and without mild cognitive decline. Data on medication
adherence was obtained at baseline, 3- and 6-months using the Basel Assessment of Adherence
Scale (BAASIS). Regression analysis was used to clarify the contribution of EDS and cognition to
medication adherence and to assess relationships over six months after adjusting for age,
enrollment site, gender, race, functional class, depression, and premorbid intellect.
Results—At baseline, 62% of subjects were nonadherent to their medication regime.
Nonadherence was significantly more common in those with EDS, regardless of cognitive status
(p=0.035). The odds of nonadherence increased by 11% for each unit increase in EDS
(AOR=1.11, 95% CI=1.05–1.19, p=0.001). In longitudinal models there was a 10% increase in the
odds of nonadherence for each unit increase in EDS (p=0.008). The only cognition measure
significantly associated with medication adherence was attention (p=0.047).
Conclusion—Adults with HF and EDS are more likely to have problems adhering to their
medication regimen than those without EDS, regardless of their cognitive status. Identifying and
correcting factors that interfere with sleep may improve medication adherence.
Keywords
heart failure; sleep; excessive daytime sleepiness; cognition; vigilance; patient compliance; self-
care
Introduction
Poor self-care—encompassing treatment adherence, symptom monitoring, and management
of symptoms—remains the most common reason for unplanned hospitalization in adults
with heart failure (HF).(1–3) Medication adherence, in particular, is integral to controlling
volume overload and symptoms, improving functioning and quality of life, and preventing
acute decompensation in adults with HF.(4–6) Yet, self-care remains poor in HF patients.(7,
8) Initiatives to improve HF self-care have had limited success,(9) suggesting that important
operative factors have not been identified and considered.
A 2006 Institute of Medicine report called national attention to the devastating effects of
daytime sleepiness, including potential problems with treatment adherence.(10) Excessive
daytime sleepiness (EDS) is the term used to describe decreased attention and increased
sleep propensity during wakeful states.(11, 12) Sleep propensity reflects the interaction of
homeostatic mechanisms that regulate sleep intensity, and circadian rhythm, which regulates
the timing of sleep.(13, 14) The relative strength of the sleep and wake drives reflects
chronobiological and environmental factors such as physical activity, which stimulate
arousal.(15) In adults with HF, contributors to EDS include older age, sleep disordered
breathing, insomnia, depression, and polypharmacy, often with medications that cause
somnolence as a primary side effect.(16–19)
Critical, yet unexplored, is the contribution of EDS to poor self-care in HF patients. We
hypothesized that EDS may impair self-care through its effects on cognition.(20, 21)
Inadequate sleep has been shown to impair information processing, memory, vigilance,
judgment, motivation, and decision-making across a wide range of populations.(22–24)
Most of these cognitive domains are also susceptible to decline in people with HF,(25, 26)
25% to 50% of whom have impaired cognition.(27) Therefore, the primary objective of this
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study was to determine if medication adherence differs in adults with HF and EDS
compared to adults with HF but without EDS and to test cognition as the mechanism of the
effect.
Methods
A prospective cohort comparison study was conducted to test the hypothesis that a cohort of
adults with HF and EDS would, over time, experience more problems with medication
adherence than a cohort with HF but without EDS. A consecutive sample of 280 adults with
HF was enrolled from three outpatient settings in Philadelphia, Pennsylvania and Newark,
Delaware. Data were collected between 2007 and 2010.
Inclusion criteria specified enrollment of adults with chronic Stage C HF confirmed based
on echocardiographic and clinical evidence. Potential subjects were screened to discern their
abilities to participate in the study (e.g., visual acuity sufficient to read study materials,
hearing sufficient to engage in a dialogue, and English literacy sufficient to enable accurate
cognition testing).(28) We included subjects with mild cognitive decline(29) as measured by
the Telephone Interview of Cognitive Status (TICS).(30) The TICS is composed of 11 items,
with a maximum score of 41; high scores indicate less impairment. A score in the range of
21–25 suggests mild cognitive decline. We sought to enroll individuals with mild cognitive
decline so anyone with a TICS score ≥ 24 was included.
Otherwise eligible individuals were excluded if they lived in a long term care setting where
self-care was not a reasonable expectation or worked nights or rotating shifts, or if they had
renal failure requiring dialysis, an imminently terminal illness, plans to move out of the area,
a history of serious drug or alcohol abuse within the past year, or major depression (Figure
1). Major depression was identified in two ways: patients described in the medical record as
having major depressive illness were not contacted. In addition, everyone was screened with
the 9-item Patient Health Questionnaire (PHQ-9).(31) We excluded anyone reporting 5 or
more of the 9 symptoms more than half the days in the past 2 weeks; 1 of the symptoms had
to be depressed mood or anhedonia. For those who passed screening, we continued to use a
subset of data from the PHQ-9 (i.e., the PHQ-2) at each testing interval as an indicator of
mild depressive symptoms, as described below. Most of the data were collected during home
visits by trained research assistants. Clinical information was abstracted from the medical
record by registered nurses. Sleep disordered breathing was not an exclusion criterion
because our focus was on identifying the effect of EDS on self-care, regardless of the cause.
A total of 2469 adults with HF were considered for enrollment, but only 333 were eligible to
participate. Major reasons for ineligibility were distance, illness severity, renal dialysis,
dementia or prior stroke, or living in an institutional setting. Some of these issues reflect the
university referral center where most patients were recruited. Further, because this was a
cohort study, as cohorts were saturated, patients eligibility focused on criteria related to EDS
and cognitive status, which eliminated 323 otherwise eligible individuals. A total of 280
individuals were enrolled and followed for six months. Attrition was only 13.6% (n=38)
over the six months of follow-up with data on EDS, cognition, and medication adherence
collected in person at baseline, 3- and 6-months..
Using data collected at baseline, we identified a cohort with EDS and a control group
without EDS using the Epworth Sleepiness Scale. Both groups were further divided into
those with and without mild cognitive decline, as described below.
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Measurement
Daytime Sleepiness—Excessive daytime sleepiness was measured with the Epworth
Sleepiness Scale (ESS), a validated research tool considered the gold-standard measure for
the assessment of daytime sleepiness.(32) The ESS is an 8-item self-report scale on which
respondents rated the likelihood of falling asleep in boring situations such as riding as a
passenger in a car. Test-retest reliability (r = 0.82) and internal consistency (α = 0.88) have
been established.(33) In this study, the alpha coefficient was .78. Responses on a 4-point
Likert scale are summed, with higher scores indicating greater sleepiness. Others have
shown that even HF patients with sleep disordered breathing report relatively low levels of
EDS.(34) Therefore, we used a cut-point of more than 6 for the determination of EDS on the
advice of the instrument author (Johns, personal communication, 2007).
Cognitive Decline—Sleep loss is known to affect simple and complex attention,
processing speed, working memory, short-term memory, reasoning and crystallized
cognitive ability, with simple attention most sensitive to sleep deprivation.(23) A
neuropsychological test battery measuring these major cognitive domains was administered
to all participants. The battery included the Psychomotor Vigilance Task (PVT)(35) (simple
attention), the Trail Making Test B(36) (complex attention), the Digit Symbol Substitution
Test(37) (processing speed), the Probed Recall Memory Task(38) (working memory), the
Letter Number Sequencing test(37) (short-term memory), and crystallized cognitive ability
or premorbid intellect (American National Adult Reading Test (ANART) (39) (Table 1).
The number of tests on which subjects scored below their age-based norm was used as the
measure of cognitive status.(37) Specifically, anyone scoring < 1.5 standard deviations on
two or more of the paper-and-pencil cognition tests was judged to have a mild cognitive
decline. The PVT is not influenced by practice, aptitude, or education, although it is
influenced by age and gender.(40) Therefore, age and gender were used as covariates in the
analysis, as discussed below. The ANART also was used as a covariate in analysis.(39)
Medication Adherence—Medication adherence was assessed with the Basel Assessment
of Adherence Scale (BAASIS), a structured interview assessing general medication
adherence over the past month.(41) This self-report measure was chosen over others
available because it measures both taking and timing dimensions of the medication regimen
as well as the occurrence of drug holidays; most other self-report surveys focus on
medication taking behavior only. The four dichotomous items are easy to score and
interpret. A positive answer on any of the questions classifies a patient as nonadherent with
the medication regimen. This broad definition of nonadherence compensates for the
underreporting of nonadherence common in self-reports.(42) Validity has been established
in HIV infected persons (43) and renal transplantation (Schäfer et al., work in progress)
patients.
Sociodemographic Characteristics—Sociodemographic characteristics were self-
reported. Education was categorized as less than high school, high school, or at least some
college. Subjects were asked to rate their financial income as: 1) comfortable, have more
than enough to make ends meet; 2) have enough to make ends meet; or 3) do not have
enough to make ends meet.
Most clinical information (e.g., comorbid illnesses, HF type and duration, left ventricular
ejection fraction) was gathered from the medical record by a registered nurse. Comorbidity
was scored using the Charlson Index;(44) higher scores indicate more comorbid illnesses.
(44) In addition to the score derived from the Charlson Index, we added the number of major
comorbid conditions identified in the medical record. Information on New York Heart
Association (NYHA) functional class was gathered by trained research assistants using a
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structured interview.(45) A single board-certified cardiologist scored functional class in
every subject. Length of time with HF was calculated after a historical search of each record
to identify the first mention of HF.
A physician-diagnosis of sleep disordered breathing (SDB) based on polysomnography was
obtained from the medical record at the time of enrollment. If no documentation of recent
sleep testing was found in the medical record, sleep was assessed in the home using an
unattended sleep study device, the Embletta (Medcare, Buffalo, NY). Individuals with an
apnea hypopnea index ≥ 5 were classified as having SDB.(46)
Depressive symptoms were measured over the course of the study using the PHQ-2.(31) The
PHQ-2 was used rather than the PHQ-9 to avoid symptoms related to EDS. Symptoms of
insomnia were ascertained using the Pittsburgh Sleep Quality Index.(47) Scores on
subscales for quality, latency, duration, and efficiency were added; higher scores indicate
more insomnia. Perceived or self-reported health status was measured with a single item
from the Medical Outcomes Study. Although commonly unrelated to objective ratings of
health by a physician, others have documented that HF patients who perceived their health
to be poor were more likely to be hospitalized over a 12 week period.(48) Still others have
found that perceived health was an independent predictor of cardiovascular mortality and
quality of life in older adults with HF.(49, 50)
Analysis
Demographic differences between the sleep and cognition cohorts were tested with Chi-
square or ANOVA. The primary analysis used the sleep and cognition cohorts at baseline.
Differences in medication adherence between the sleep and cognition cohorts were assessed
at baseline and at each point longitudinally (3- and 6-month follow-up points). For baseline
associations, chi square analysis followed by logistic regression analysis was used to clarify
the contribution of EDS and mild cognitive decline to medication adherence. Longitudinally,
logistic mixed effects regression models were used to assess the relationships over time.
Secondary analyses examined the Epworth Sleepiness Scale score along with each of the
independent cognition test scores. Regression models were adjusted for age, enrollment site,
gender, race, NYHA functional class, and premorbid intellect measured with the ANART.
In addition, depression was adjusted in each analysis because depression is an important
contributor to EDS (51). All analyses were conducted using SAS 9.2 (SAS Institute Inc.,
Cary, NC).
Results
Demographic characteristics at baseline by EDS and cognition cohorts are shown in Table 2.
The average subject tended to be a white (63%) male (64%) aged 62±12 years.
Approximately half (54%) of the sample had SDB. The cohorts without mild cognitive
decline tended to be younger (p<.001), have more white subjects (p=0.008), have a higher
level of education (p=0.009), not be taking a diuretic (p=0.042), and to have higher ANART
scores (p=0.001). A summary of scores on the various cognition tests are given in Table 3.
At baseline, 62% (n=171) of subjects were found to be nonadherent to their HF medication
regime (Table 4). Specific issues reported were taking medicines 2 or more hours late
(timing adherence) (46.8%), forgetting to take medicines (dosing adherence) (35.5%),
reducing the amount taken (taking adherence) (7.2%), and drug holidays or skipping
medicine doses altogether (6.8%). Medication nonadherence was significantly more
common in those with EDS, regardless of cognitive status (p=0.033) even after adjustment
for important covariates (Figure 2). Compared to subjects without EDS or cognitive decline,
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subjects with EDS and mild cognitive decline were 2.5 times more likely to be nonadherent
(AOR=2.52, 95% CI=1.18–5.38, p=0.017), while the group with EDS but without cognitive
decline was twice as likely to be nonadherent (AOR=2.36, 95% CI=1.12–4.99, p=0.025).
Secondary models using the Epworth Sleepiness Scale score and the individual cognition
test scores showed that the odds of nonadherence increased by 11% for each unit increase in
EDS (AOR=1.11, 95% CI=1.04–1.19, p=0.001) while cognitive status was not significantly
associated with medication adherence (p=0.752).
Mixed effect logistic regression models were then used to assess the changes in medication
adherence over the entire course of the study (baseline to 6-months in three month intervals).
In adjusted models (Table 5), the EDS groups were almost twice as likely to be nonadherent
compared to the cohort without either EDS or a mild cognitive decline; subjects with EDS
and mild cognitive decline were 1.6 times more likely to be nonadherent (AOR=1.61, 95%
CI=1.03–2.50, p=0.037), while the group with EDS but without cognitive decline was twice
as likely to be nonadherent (AOR=1.72, 95% CI=1.11–2.70, p=0.014).
Secondary models (Table 6) using the Epworth Sleepiness Scale score found a 9% increase
in the odds of nonadherence for each unit increase in EDS (p=0.001). Of the individual
cognition measures, only the PVT was significantly associated with medication adherence,
with a 9% increase in the odds of nonadherence for each unit increase in the number of
transformed lapses detected over a 10-minute testing interval (p=0.024).
Discussion
The major finding of this study was that self-reported medication nonadherence is
significantly higher in adults with HF who have even relatively mild rates of EDS (using a
cut-point of ≥ 6 rather than the usual cut-point of ≥ 11 on the Epworth Sleepiness Scale).
The other major finding was that the relationship between EDS and medication
nonadherence may be explained by selective attention. That is, adults with HF and EDS
appear to be missing medication doses or taking their medicines late because of poor
attention and a lack of vigilance.
The link between EDS and medication nonadherence is compelling. Most HF investigators
cite medication nonadherence rates between 40% and 60%,(52–59) which is consistent with
the rate of nonadherence identified in this study. Medication nonadherence has been shown
to be associated with hospitalization and death in adults with HF. For example, Murray and
colleagues found that hospitalization was higher in HF patients low in medication taking
adherence compared to patients who were adherent with taking their medications.(60) Wu et
al documented that medication adherence predicted event-free survival before and after
controlling for age, gender, ejection fraction, NYHA class, angiotensin-converting enzyme
inhibitor use, and beta-blocker use.(61) The findings of these authors demonstrate the
importance of medication adherence, while the results of the current study provide a focus
for interventions that may improve it.
In a recent review of the factors associated with medication nonadherence, forgetfulness was
one of the most common barriers to adherence identified.(62) This result is supported and
explained by our finding that attention may be the mechanism by which EDS influences
medication nonadherence. Lim and Dinges argue that the ability to sustain attention is
fundamental to all other aspects of cognition and that vigilance is the process most affected
by sleep deprivation.(63) If alertness and sustained attention are necessary for successful
information processing, memory, judgment, and decision-making, HF patients with EDS
may not be able to sustain the attention needed to remember to take their medicines with any
regularity.
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Only one prior study of sleepiness and medication adherence was located. In a study of 173
HIV infected women, Phillips et al.(64) found a significant difference in adherence to highly
active antiretroviral therapy between good sleepers and poor sleepers. Elements of cognition
such as vigilance were not tested as mediators in this study. They did find, however, that
depression mediated the relationship between sleep and medication adherence, which was
not surprising in this population. The women were single, low income, African-American
women, 39 years of age, on average, living in a rural community. In our HF population, both
depression and impaired cognition are common issues and depression was adjusted in our
analyses. But, future research should explore the contribution of depression to the
relationship between EDS and adherence.
Strengths of the current study include a large sample enrolled from three diverse sites and
the relatively large sample of women and minorities. The primary limitation of this study is
the self-report method of assessing medication adherence, although self-report is generally
considered a central component of adherence assessment. It is possible that subjects with a
mild cognitive decline may not remember if they took their medications. However,
inaccuracies in the self-report approach most likely would under report the occurrence of
skipped doses and late administrations. Thus, true medication nonadherence is most likely
even higher than the self-reported rate presented here. In addition, demographic differences
in age, education, race, and premorbid intellect between the cohorts is a limitation that is
difficult to account for statistically and complicates our interpretation of the cognitive tests.
Selection bias is possible also, as many patients were ineligible for inclusion in the study.
Further, it is plausible that subjects with cognitive decline may have been adherent to the
medication regimen because a caregiver assured adherence. This possibility was not
accounted for in the analysis.
Further research is needed to describe the factors other than sleep quality influencing simple
attention or vigilance in this population; it may be that these factors could be amenable to
intervention. It would also be useful to test an association between EDS and other forms of
self-care prescribed for adults with HF. It may be that EDS is also associated with failure to
comply with daily weighing, a sodium restricted diet, and the response to symptoms when
they occur. Research is also needed to describe how EDS changes over time in adults with
HF. It has already been established that persons with HF do not experience as much EDS as
other adults in the same age group.(34) However, further research is needed to explain this
observation.
In summary, we found that even a relatively low level of EDS is associated with
significantly more self-reported medication nonadherence in adults with HF. An inability to
maintain vigilance and pay attention may be the mechanism responsible for the link between
EDS and medication nonadherence in adults with HF.
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Figure 1.
Flow of Participants Through the Study
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Figure 2. Baseline medication adherence by EDS and mild cognitive decline cohorts
Illustration of the finding that reported medication nonadherence was significantly higher in
the two cohorts with excessive daytime sleepiness, regardless of whether or not they had a
mild cognitive decline.
EDS = excessive daytime sleepiness
MCD = mild cognitive decline
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Table 4
Baseline medication adherence by sleep and cognition cohorts.
+EDS, +MCD +EDS, no MCD no EDS, +MCD no EDS, no MCD
Nonadherent to medications (61.4%) 56 (68.3%) 56 (73.7%) 29 (49.1%) 31 (49.2%)
Adherent to medications (38.6%) 26 (31.7%) 20 (26.3%) 30 (50.9%) 32 (50.8%)
EDS = excessive daytime sleepiness
MCD = mild cognitive decline
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Table 5
Final mixed effects logistic regression model for longitudinal medication adherence. Odds of being adherent
are shown.
Variable AOR1 95% CI p-value
Sleep and cognition cohorts
 no EDS, no MCD (ref)
 no EDS, + MCD 1.01 0.63–1.61 0.975
 +EDS, no MCD 0.58 0.37–0.90 0.014
 +EDS, + MCD 0.62 0.40–0.97 0.037
Time 0.99 0.93–1.05 0.824
NYHA functional class
 NYHA class I or II (ref)
 NYHA class III 1.25 0.86–1.82 0.234
 NYHA class IV 1.27 0.76–2.12 0.364
PHQ2 Depression Score 0.91 0.79–1.04 0.160
1
Model also adjusted for site, age, gender, and race. (ref=reference group for AOR).
EDS = excessive daytime sleepiness
MCD = mild cognitive decline
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Table 6
Mixed effects logistic regression models for longitudinal medication adherence based on individual cognitive
tests. Odds of being adherent are shown.
Variable AOR1 95% CI p-value
Model 1:
 Epworth Total Score 0.93 0.89–0.97 0.001
 PVT Transformed Lapses 0.94 0.89–0.99 0.024
Model 2:
 Epworth Total Score 0.92 0.88–0.95 <.001
 Digit Symbol Substitution Test 0.99 0.98–1.01 0.337
Model 3:
 Epworth Total Score 0.92 0.89–0.96 <.001
 Probed Memory Recall task 1.01 0.88–1.17 0.837
Model 4:
 Epworth Total Score 0.92 0.89–0.96 <.001
 Letter Number Sequencing Subtest 0.75 0.39–1.44 0.381
Model 5:
 Epworth Total Score 0.92 0.88–0.96 <.001
 Trial Making Test B 1.00 1.00-1.00 0.757
1
Models also adjusted for site, age, gender, race, ANART score, NYHA class, PHQ2 depression score, diuretic use, and visit time.
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